{"disease":{"id":"myelomatosis","name":"myelomatosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04782687","title":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":73,"lead_sponsor_name":"US Oncology Research","has_results":false},{"nct_id":"NCT05153330","title":"Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":55,"lead_sponsor_name":"Biomea Fusion Inc.","has_results":false},{"nct_id":"NCT01239368","title":"Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02057640","title":"MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Jason Valent","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}